PMID- 37107136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230430
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 12
IP  - 4
DP  - 2023 Apr 18
TI  - The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of 
      Diabetic Foot Infections: A Narrative Review of the Literature.
LID - 10.3390/antibiotics12040774 [doi]
LID - 774
AB  - The use of antibiotics for the treatment of diabetic foot infections (DFIs) over 
      an extended period of time has been shown to be associated with adverse events 
      (AEs), whereas interactions with concomitant patient medications must also be 
      considered. The objective of this narrative review was to summarize the most 
      frequent and most severe AEs reported in prospective trials and observational 
      studies at the global level in DFI. Gastrointestinal intolerances were the most 
      frequent AEs, from 5% to 22% among all therapies; this was more common when 
      prolonged antibiotic administration was combined with oral beta-lactam or 
      clindamycin or a higher dose of tetracyclines. The proportion of symptomatic 
      colitis due to Clostridium difficile was variable depending on the antibiotic 
      used (0.5% to 8%). Noteworthy serious AEs included hepatotoxicity due to 
      beta-lactams (5% to 17%) or quinolones (3%); cytopenia's related to linezolid 
      (5%) and beta-lactams (6%); nausea under rifampicin, and renal failure under 
      cotrimoxazole. Skin rash was found to rarely occur and was commonly associated 
      with the use of penicillins or cotrimoxazole. AEs from prolonged antibiotic use 
      in patients with DFI are costly in terms of longer hospitalization or additional 
      monitoring care and can trigger additional investigations. The best way to 
      prevent AEs is to keep the duration of antibiotic treatment short and with the 
      lowest dose clinically necessary.
FAU - Soldevila-Boixader, Laura
AU  - Soldevila-Boixader L
AUID- ORCID: 0000-0003-0649-3785
AD  - Infectious Diseases Service, IDIBELL-Hospital Universitari Bellvitge, Universitat 
      de Barcelona, Feixa Llarga s/n, Hospitalet de Llobregat, 08907 Barcelona, Spain.
AD  - Research Network for Infectious Diseases (CIBERINFEC), ISCIII, 28029 Madrid, 
      Spain.
AD  - Infectiology, Unit for Clinical and Applied Research, Balgrist University 
      Hospital, 8008 Zurich, Switzerland.
FAU - Murillo, Oscar
AU  - Murillo O
AD  - Infectious Diseases Service, IDIBELL-Hospital Universitari Bellvitge, Universitat 
      de Barcelona, Feixa Llarga s/n, Hospitalet de Llobregat, 08907 Barcelona, Spain.
AD  - Research Network for Infectious Diseases (CIBERINFEC), ISCIII, 28029 Madrid, 
      Spain.
FAU - Waibel, Felix W A
AU  - Waibel FWA
AUID- ORCID: 0000-0003-3991-8743
AD  - Department of Orthopedics, Balgrist University Hospital, University of Zurich, 
      8008 Zurich, Switzerland.
FAU - Huber, Tanja
AU  - Huber T
AD  - Hospital Pharmacy, Balgrist University Hospital, 8008 Zurich, Switzerland.
FAU - Schoni, Madlaina
AU  - Schoni M
AD  - Department of Orthopedics, Balgrist University Hospital, University of Zurich, 
      8008 Zurich, Switzerland.
FAU - Lalji, Rahim
AU  - Lalji R
AUID- ORCID: 0000-0002-7129-2544
AD  - EBPI-UWZH Musculoskeletal Epidemiology Research Group, Balgrist University 
      Hospital, University of Zurich, 8008 Zurich, Switzerland.
AD  - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of 
      Zurich, 8008 Zurich, Switzerland.
AD  - University Spine Centre Zurich (UWZH), Balgrist University Hospital, University 
      of Zurich, 8008 Zurich, Switzerland.
FAU - Uckay, Ilker
AU  - Uckay I
AUID- ORCID: 0000-0002-5552-0973
AD  - Infectiology, Unit for Clinical and Applied Research, Balgrist University 
      Hospital, 8008 Zurich, Switzerland.
AD  - Department of Orthopedics, Balgrist University Hospital, University of Zurich, 
      8008 Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230418
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC10135215
OTO - NOTNLM
OT  - antibiotic therapy
OT  - antibiotic-related adverse events
OT  - diabetic foot infection
OT  - management
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/28 06:41
MHDA- 2023/04/28 06:42
PMCR- 2023/04/18
CRDT- 2023/04/28 01:19
PHST- 2023/03/26 00:00 [received]
PHST- 2023/04/16 00:00 [revised]
PHST- 2023/04/17 00:00 [accepted]
PHST- 2023/04/28 06:42 [medline]
PHST- 2023/04/28 06:41 [pubmed]
PHST- 2023/04/28 01:19 [entrez]
PHST- 2023/04/18 00:00 [pmc-release]
AID - antibiotics12040774 [pii]
AID - antibiotics-12-00774 [pii]
AID - 10.3390/antibiotics12040774 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2023 Apr 18;12(4):774. doi: 10.3390/antibiotics12040774.